^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

pradusinstobart (LVGN3616)

i
Other names: LVGN3616, LVGN 3616
Associations
Company:
Lyvgen
Drug class:
PD1 inhibitor
Related drugs:
Associations
5ms
CD40 Agonist and PD-1 Inhibitor in HNSCC (clinicaltrials.gov)
P1, N=20, Not yet recruiting, University of Pennsylvania
New P1 trial
|
dalnicastobart (LVGN7409) • pradusinstobart (LVGN3616)
8ms
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=352, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jul 2023 --> Feb 2027 | Trial primary completion date: Jul 2023 --> Feb 2027
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CD40 (CD40 Molecule)
|
Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
over2years
Study of LVGN3616 and LVGN6501±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=352, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Nov 2021
Enrollment open • Trial initiation date • Combination therapy
|
CD40 (CD40 Molecule)
|
Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
over2years
New P1 trial • Combination therapy
|
CD40 (CD40 Molecule)
|
Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)